GlassScriptPhysician profile
Abdul M Khan
NPI 1902123995
$587,403.54
in general payments reported to CMS, 2019-2025
45 companies · $44K in 2025
The $44K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92K · 2020: $68K · 2021: $133K · 2022: $149K · 2023: $57K · 2024: $45K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $28K · Travel and Lodging: $26K · Consulting Fee: $9,625 · Food and Beverage: $7,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,398.22 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $27,600.00 |
| Travel and Lodging | $26,239.36 |
| Consulting Fee | $9,625.00 |
| Food and Beverage | $7,957.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $206,270.22 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Novo Nordisk INC | $200,649.38 | 2019-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $120,753.03 | 2019-2025 | |
| Abbott Laboratories | $51,922.23 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Merck Sharp & Dohme LLC | $1,909.43 | 2019 | |
| Medtronic, INC. | $767.54 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $636.10 | 2019-2024 | Cycloset |
| Astrazeneca Pharmaceuticals LP | $433.70 | 2019-2020 | |
| Dexcom, INC. | $384.33 | 2020-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $378.75 | 2019-2025 | |
| Alkermes, INC. | $337.51 | 2024-2025 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.07 | 2019-2023 | Jardiance, Tradjenta |
| Beta Bionics, INC. | $253.38 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $237.30 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $232.34 | 2022-2025 | Evenity, Prolia, Tepezza |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $216.32 | 2019-2025 | Korlym |
| Becton, Dickinson and Company | $170.93 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $165.10 | 2019-2024 | |
| Radius Health, INC. | $163.53 | 2019-2025 | Tymlos |
| Medtronic Minimed, INC. | $155.26 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.03 | 2023-2025 | |
| Insulet Corporation | $100.58 | 2019-2025 | Omnipod |
| Amarin Pharma, INC. | $82.60 | 2019 | |
| Shire North American Group INC | $81.35 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $71.00 | 2023-2025 | Imcivree, Imcivree |
| Ascendis Pharma Endocrinology INC | $60.45 | 2024-2025 | Yorvipath |
| Ardelyx, INC. | $59.76 | 2024 | Ibsrela |
| Esperion Therapeutics, INC. | $51.50 | 2023-2025 | Nexletol |
| Pfizer INC. | $44.77 | 2023-2025 | |
| Zealand Pharma US, INC. | $37.87 | 2020-2021 | |
| Sequel Med Tech, LLC | $36.53 | 2025 | Twiist |
| Phathom Pharmaceuticals, INC. | $31.05 | 2024 | Voquezna |
| Mannkind Corporation | $29.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $27.50 | 2024 | |
| Tandem Diabetes Care, INC. | $25.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $22.89 | 2023 | Crysvita |
| Valeritas, INC. | $22.64 | 2019 | |
| Bausch Health US, LLC | $21.58 | 2023 | Wellbutrin, Aplenzin |
| Nevro Corp. | $20.42 | 2023 | Senza |
| Ibsa Pharma INC. | $20.06 | 2025 | Tirosint, Flector, Licart |
| Averitas Pharma INC. | $18.47 | 2023 | Qutenza |
| Evoke Pharma, INC. | $17.36 | 2025 | |
| Amneal Pharmaceuticals LLC | $16.45 | 2025 | Unithroid |
| Recordati_rare_diseases_inc. | $16.01 | 2024 | Signifor Lar, Isturisa |
| Adlon Therapeutics L.P. | $14.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.